Abiopharma

New Form 4 - Entrada Therapeutics, Inc. Filed: 2025-06-12 AccNo: 0001689375-25-000033 Size: 5 KB

New Form 10-Q - enGene Holdings Inc. Filed: 2025-06-12 AccNo: 0000950170-25-085143 Size: 10 MB

New Form 4 - Entrada Therapeutics, Inc. Filed: 2025-06-12 AccNo: 0001689375-25-000032 Size: 5 KB

enGene Reports Second Quarter 2025 Financial Results and Provides Business Update

New Form 4 - Entrada Therapeutics, Inc. Filed: 2025-06-12 AccNo: 0001689375-25-000031 Size: 5 KB

New Form 8-K - enGene Holdings Inc. Filed: 2025-06-12 AccNo: 0000950170-25-085138 Size: 382 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

New Form 4 - Entrada Therapeutics, Inc. Filed: 2025-06-12 AccNo: 0001689375-25-000030 Size: 5 KB

New Form DEFA14A - SPRUCE BIOSCIENCES, INC. Filed: 2025-06-12 AccNo: 0000950170-25-085137 Size: 29 KB

Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients

New Form 8-K - Nurix Therapeutics, Inc. Filed: 2025-06-12 AccNo: 0001549595-25-000086 Size: 6 MB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics, Inc. to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

ImmunoPrecise - AI-Designed GLP-1 Peptides from ImmunoPrecise Antibodies Surpass Semaglutide in Receptor Activation Studies

Third Harmonic Bio Announces Stockholder Approval of Plan of Liquidation and Dissolution, Updated THB335 Phase 1 Clinical Data, and Initiation of Sale of THB335

Amneal Pharmaceuticals, Inc. - Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension

Spruce Biosciences Announces Conditional Nasdaq Approval to Resume Trading on the Nasdaq Capital Market